Acadia Pharma (ACAD) Misses Q2 EPS by 6c; Lowers Outook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results
August 8, 2018 4:05 PM EDTSecond Quarter Net Sales Grew to $57.1 Million, Representing a 17% Sequential Increase Over 1Q18 and 87% Increase Over 2Q17
Announced FDA Approval of New Dosing Formulation and Strength of NUPLAZID® (Pimavanserin)
Expanded ACADIAs Pipeline in Central Nervous System Disorders with Exclusive License Agreement for the North American Development and Commercialization of Trofinetide
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,... More
